Comparing the Efficacy of @entity752 and @entity7776 on XXXX Induced by a Selective @entity750 Reuptake Inhibitor.

@entity1 @entity7776 @entity750 @entity752 @entity250
BACKGROUND: Antidepressant-induced @entity250 ( @entity250 ) is a common problem, associated with a significant risk of non-adherence. Selective @entity750 Reuptake Inhibitors (SSRIs) are associated with a substantial risk of @entity250 . Only 10 % of @entity1 show spontaneous improvement during follow up period. OBJECTIVES: This study aimed to compare two proposed medication ( @entity752 vs. @entity7776 ) in alleviating @entity250 in @entity1 treated with SSRIs. @entity1 AND METHODS: In a randomized, single-blinded, clinical trial in Iran, 46 @entity1 were recruited based on DSM-IV-TR criteria and semi-structured interview. Then, they were randomized into two treatment groups using table of random numbers. Eight @entity1 were excluded and finally 38 @entity1 completed the study which lasted for 4 weeks. Twenty @entity1 were given @entity752 , 18 @entity1 were randomly assigned to another group, and given @entity7776 . @entity1 were assessed with the Arizona sexual experience scale (ASEX) at baseline and 4 weeks after the treatment. RESULTS: A total of 38 @entity1 completed the study (18 @entity1 in @entity7776 vs. 20 @entity1 in @entity752 ).The mean ASEX scores gradually declined in both study groups during the trial. The reduction of ASEX score in @entity752 group was more than that of @entity7776 group that was statistically significant. So, the addition of @entity752 at higher doses appears to be more effective approach in comparison with @entity7776 . CONCLUSIONS: These results provide empirical support for conducting a further study on comparing different add-on strategies for treating drug-induced @entity250 .
